With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes. IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information.
Watch the video below.
Immuno-assays with high specificity and sensitivity are a powerful tool, however, there are challenges associated with antibody based multiplexing when you wish to concurrently analyze beyond 2-3 markers.
A multiplex IHC solution that bypasses antibody species/isotype concerns, while providing signal amplification, was used to examine the co-expression of immune checkpoint control proteins, such as PD-L1, B7-H3, B7-H4, and VISTA, in breast and ovarian cancer.
| Matthew Silver received his PhD in Biochemistry from the University of New Hampshire where he studied the neuroendocrine regulation of reproduction. His subsequent postdoctoral studies were performed at Wyeth Research within the Department of Inflammation. |
Want to learn more? Click/tap the button below to download an application note on the use of multiplex IHC to investigate immune checkpoint markers and T cell exhaustion.